• Advertise
  • Contact Us
  • Write For Us
  • Our Team
Extraction Magazine
No Result
View All Result
  • Botanical Extraction
    • Cannabinoids
    • Psychedelics
    • Nutraceutical
    • Product Refinement
  • Industry News
    • Business
    • Sustainability
    • Safety & Compliance
    • Partners
  • Extraction Technology
    • Equipment
    • Methods
    • Solvents
    • DIY Extraction
    • Analytical Techniques
  • Medical Research
  • Glossary
  • Business Directory
  • Botanical Extraction
    • Cannabinoids
    • Psychedelics
    • Nutraceutical
    • Product Refinement
  • Industry News
    • Business
    • Sustainability
    • Safety & Compliance
    • Partners
  • Extraction Technology
    • Equipment
    • Methods
    • Solvents
    • DIY Extraction
    • Analytical Techniques
  • Medical Research
  • Glossary
  • Business Directory
No Result
View All Result
Extraction Magazine
No Result
View All Result
Home Industry News Press Releases

InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System

Shared Content by Shared Content
July 19, 2020
in Press Releases
InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System

VANCOUVER, BC, June 24, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today introduced details of IntegraSynTM, the Company’s new approach to producing pharmaceutical-grade cannabinoids. IntegraSynTM is a manufacturing system that integrates biosynthesis with other traditional drug manufacturing methods with the goal of improving production of low-cost, high quality cannabinoids.

As announced on May 5, 2020, IntegraSynTM is being developed in collaboration with contract development and manufacturing organizations in order to be able to flexibly shift from production of one cannabinoid to another.  The Company recently expanded its program with one of its collaborators to include additional R&D for this manufacturing approach.

READ ALSO

The Delta 8 Expo in Partnership with The CBD Expo Tour Heads to Orlando, FL to Wrap Up its ‘22 tour… With a New Twist

Delta 8 / CBD Expo Anticipates the Recently Passed Cannabinoid Derivatives Bill in Minnesota Presenting Perfect Timing for Product Sales

The goals of IntegraSynTM are to:

  • increase yields beyond traditional biosynthesis or other standard cannabinoid manufacturing methods;
  • reduce costs by minimizing the number of expensive manufacturing steps and use of cost-efficient starting materials;
  • provide manufacturing flexibility in transitioning from one cannabinoid to another;
  • provide access to rare cannabinoids that are otherwise impractical / expensive to extract from the plant;
  • be scalable to meet market demand of cannabinoids for pharmaceutical products or other purposes; and
  • use a sustainable approach with less environmental impact than the plant-grow-harvest-extract-purify methods.

IntegraSynTM is an integrated process that begins with a bacterial-based fermentation step generating a proprietary, high efficiency enzyme in bulk and at low cost.  On an as-needed basis, this enzyme is combined with sophisticated yet cost-efficient substrates in a biotransformation vessel, leading to cannabinoid assembly. Industry standard purification processes and equipment are used to produce a high-purity cannabinoid that acts as the active pharmaceutial ingredient (“API”), which could be inventoried or used as a product for pharmaceutical R&D or for direct commercialization.  In addition, the IntegraSynTM process affords the flexibility for this cannabinoid to be further processed, via either chemical synthesis or via an additional enzyme-driven biotransformation process followed by further purification, resulting in a different cannabinoid API.

About InMed: InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com.

About IntegraSynTM: IntegraSynä is InMed’s integrated cannabinoid manufacturing system designed to efficiently and economically produce pharmaceutical-grade, bio-identical cannabinoids. The scalable and flexible IntegraSyn™ manufacturing system integrates multiple commercially proven methods to efficiently produce cannabinoids utilizing cost-effective processes.

Cautionary Note Regarding Forward-Looking Information:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes, but is not limited to, statements about: leading the way in the clinical development of cannabinol (CBN); being developed in collaboration with contract development and manufacturing organizations in order to be able to flexibly shift from production of one cannabinoid to another; increasing yields beyond traditional biosynthesis or other standard cannabinoid manufacturing methods; reducing costs by minimizing the number of expensive manufacturing and use of cost-efficient starting materials; providing manufacturing flexibility in transitioning from one cannabinoid to another; providing access to rare cannabinoids that are otherwise impractical / expensive to extract from the plant; being scalable to meet market demand of cannabinoids for pharmaceutical products or other purposes; using a sustainable approach with less environmental impact than the plant-grow-harvest-extract-purify methods; the ability of the API to be inventoried or used as a product for pharmaceutical R&D or for direct commercialization; efficiently and economically producing pharmaceutical-grade, bio-identical cannabinoids; developing medications targeting diseases with high unmet medical need; and delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to continue to successfully develop IntegraSynTM; the ability of IntegraSynTM to meet its specified goals; the ability to obtain adequate supplies; the continued availability of development collaborators; continued and timely positive preclinical and clinical efficacy data; the speed of regulatory approvals; the effectiveness of patent protection; demand for InMed’s products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: InMed’s proprietary IntegraSynTM manufacturing process and drug development programs may not deliver the expected level of results; InMed’s supply chain may become disrupted; InMed’s development collaborators may become unavailable; InMed may not be able to advance its other product candidates on a timely basis, or at all; regulatory filings may not be filed or approved on a timely basis, or at all; clinical trials may not proceed as anticipated; economic or market conditions may worsen; InMed’s may not be able to successfully access the capital required to fully develop its programs; and InMed may not be able to provide new therapeutic alternatives that benefit patients via cannabinoid-based medicines. A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s most recent Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE InMed Pharmaceuticals Inc.

Related Posts

The Delta 8 Expo in Partnership with The CBD Expo Tour Heads to Orlando, FL to Wrap Up its ‘22 tour… With a New Twist
Press Releases

The Delta 8 Expo in Partnership with The CBD Expo Tour Heads to Orlando, FL to Wrap Up its ‘22 tour… With a New Twist

August 31, 2022
Delta 8 / CBD Expo Anticipates the Recently Passed Cannabinoid Derivatives Bill in Minnesota Presenting Perfect Timing for Product Sales
Press Releases

Delta 8 / CBD Expo Anticipates the Recently Passed Cannabinoid Derivatives Bill in Minnesota Presenting Perfect Timing for Product Sales

May 31, 2022
MACE Media Group’s Delta 8 Expo in Partnership with The CBD Expo Tour Becomes the Official Host of the Platform to #KeepHempLegal Campaign in North Carolina
Press Releases

MACE Media Group’s Delta 8 Expo in Partnership with The CBD Expo Tour Becomes the Official Host of the Platform to #KeepHempLegal Campaign in North Carolina

May 12, 2022
The Delta 8 + Conversions Expo in Partnership with The CBD Expo TOUR Brings Its Industry Leading Event to North Carolina
Press Releases

The Delta 8 + Conversions Expo in Partnership with The CBD Expo TOUR Brings Its Industry Leading Event to North Carolina

April 25, 2022
The Delta 8 Expo and Delta 9 Expo Exceed Industry Expectations in Dallas, TX
Press Releases

The Delta 8 Expo and Delta 9 Expo Exceed Industry Expectations in Dallas, TX

April 8, 2022
MACE Media Group Appoints New Managing Editor
Press Releases

MACE Media Group Appoints New Managing Editor

April 5, 2022
Next Post
Gallup: Seven in Ten Americans Say That “Smoking Marijuana” Is Morally Acceptable

Gallup: Seven in Ten Americans Say That “Smoking Marijuana” Is Morally Acceptable

LATEST ARTICLES

Green Extraction Techniques

Green Extraction Techniques and Smart Solvents for Bioactive Recovery

January 10, 2025
Wide angle view at two workers wearing protective suits while inspecting production at modern chemical plant, copy space

Collaborative Approaches in Botanical Extraction: Bridging Science and Industry

January 7, 2025
Areca Catechu

Inside the Betel Nut High: Exploring the Mind-Bending Effects of Areca Catechu

January 1, 2025
The Art of Extraction: Unlocking Nature’s Fragile Secrets

The Art of Extraction: Unlocking Nature’s Fragile Secrets

December 27, 2024

Subscribe Now

Subscribe to our newsletter now to receive quick updates from us



    Background
    About

    Extraction Magazine is the trusted provider of botanical extraction news, ever-changing politics, cool gadgets and technologies, and methods for producing safe, ethical, and compliant formulations.

    Advertisers
    Navigation
    • Botanical Extraction
    • Industry News
    • Extraction Technology
    • Medical Research
    • Glossary
    • Business Directory
    Recent Posts
    • Green Extraction Techniques and Smart Solvents for Bioactive Recovery
    • Collaborative Approaches in Botanical Extraction: Bridging Science and Industry
    • Inside the Betel Nut High: Exploring the Mind-Bending Effects of Areca Catechu
    • The Art of Extraction: Unlocking Nature’s Fragile Secrets
    Subscribe to our Newsletter
    loader

    Sitemap

    © 2025 Extraction Magazine is the trusted provider of botanical extraction news and the leading media in the ever-changing extraction industry.

    No Result
    View All Result
    • Industry News
    • Botanical Extraction
    • Medical Research
    • Medical Research
    • Glossary
    • Our Team
    • Write For Us

    © 2023 Extraction Magazine is the trusted provider of botanical extraction news and the leading media in the ever-changing extraction industry.